



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 


# PRODUCT INFORMATION



**ARN25062**

Item No. 39615

**CAS Registry No.:** 3036492-85-7  
**Formal Name:** 6-phenyl-2-(4-piperidiny)-N-[3-(trifluoromethyl)phenyl]-4-pyrimidinamine  
**MF:** C<sub>22</sub>H<sub>21</sub>F<sub>3</sub>N<sub>4</sub>  
**FW:** 398.4  
**Purity:** ≥95%  
**Supplied as:** A solid  
**Storage:** -20°C  
**Stability:** ≥2 years  
**Special Conditions:** Store under nitrogen



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

## Laboratory Procedures

ARN25062 is supplied as a solid. A stock solution may be made by dissolving the ARN25062 in the solvent of choice, which should be purged with an inert gas. ARN25062 is slightly soluble (0.1-1 mg/ml) in acetonitrile and sparingly soluble (1-10 mg/ml) in DMSO.

## Description

ARN25062 is a derivative of ARN22089, an inhibitor of the protein-protein interaction between Cdc42 and p21-activated kinase (PAK).<sup>1</sup> It inhibits the proliferation of SKM28, SK-MEL-3, WM3248, and A375 melanoma cells (IC<sub>50</sub>s = 6.1, 4.6, 9.3, and 5.1 μM, respectively) and SW480 colon cancer cells (IC<sub>50</sub> = 5.9 μM). ARN25062 (10 mg/kg) reduces tumor growth in a patient-derived xenograft (PDX) mouse model.

## Reference

1. Brindani, N., Vuong, L.M., Acquistapace, I.M., *et al.* Design, synthesis, *in vitro* and *in vivo* characterization of CDC42 GTPase interaction inhibitors for the treatment of cancer. *J. Med. Chem.* **66**(8), 5981-6001 (2023).

### WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

### SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

### WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 06/20/2024

## CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD  
ANN ARBOR, MI 48108 · USA

**PHONE:** [800] 364-9897  
[734] 971-3335

**FAX:** [734] 971-3640

CUSTSERV@CAYMANCHEM.COM  
WWW.CAYMANCHEM.COM